ImmuneOncia Therapeutics and Lonza signed a manufacturing agreement for late-stage clinical supply of Danburstotug (IMC-001), a fully human PD-L1 immune checkpoint antibody in clinical investigation for relapsed/refractory NK/T-cell lymphoma. Lonza will support development and clinical manufacturing for both drug substance and drug product, with substance produced in Slough (UK) and drug product development and manufacturing across Basel and Stein (CH). ImmuneOncia said it plans to target the rare indication for early approval, and it positioned the collaboration as a foundation for future licensing and international market entry. For biotech partners, late-stage supply deals like this can de-risk CMC timelines—especially when multi-site capabilities and regulatory track records are required to keep clinical enrollment and submission calendars on track.